CLINICAL TRIALS PROFILE FOR DICLOFENAC

505(b)(2) Clinical Trials for diclofenac

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT02068859 ↗	Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1%	Unknown status	FPR Specialty Pharmacy	Phase 3	2014-01-01	Non-steroidal anti-inflammatory medication (NSAID) therapy is a mainstay treatment for joint pain and painful musculoskeletal disorders. Though this form of systemic therapy is highly effective, it causes substantial side effects including gastritis and gastric ulcer disease, renal impairment, hypertension, and thrombotic events. These types of oral medications are utilized by millions of Americans on a fairly regular basis in both over-the-counter preparations and prescription compounds. In recent years, topical preparations of NSAIDs have been used for localized pain as an alternate to oral administration with reported good analgesic efficacy. For example, they are often used for knee pain. There is little systemic absorption of NSAIDs with topical administration, and consequently less likelihood of systemic side effects. Though much less studied than oral NSAIDs, topical NSAID preparations are currently prescribed for a variety of arthritic and musculoskeletal types of pain. The best-studied commercially available products are diclofenac 1% compounds. Higher concentrations presumably provide higher tissue concentration leading to better and longer pain relief, along with a more prominent anti-inflammatory effect. The investigators will therefore compare the efficacy of available topical diclofenac 1% gel to that of diclofenac 8% cream. Specifically, the investigators propose to test the hypothesis that efficacy of topical diclofenac 8% exceeds that of diclofenac 1%, without any increase in systemic toxicity. One hundred six patients presenting to the Cleveland Clinic Pain Management Department for the treatment of knee pain will be randomly assigned to topical diclofenac cream 8% or diclofenac gel 1%, with the designated medication applied the symptomatic area of the knee over 6 weeks. Investigators will be blinded to treatment, and will evaluate pain relief and functional/disability status.
New Formulation	NCT03766984 ↗	Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac	Completed	Grünenthal Colombiana S.A.	Phase 1	2015-06-07	The objective of the study was to evaluate whether or not there is a substantial pharmacokinetic interaction between diclofenac and tramadol in a new formulation of a fixed-dose combination of diclofenac 25 milligrams (mg) and tramadol 25 mg for oral administration. The study was conducted in healthy participants of both genders.
New Formulation	NCT03766984 ↗	Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac	Completed	Grünenthal S.A.	Phase 1	2015-06-07	The objective of the study was to evaluate whether or not there is a substantial pharmacokinetic interaction between diclofenac and tramadol in a new formulation of a fixed-dose combination of diclofenac 25 milligrams (mg) and tramadol 25 mg for oral administration. The study was conducted in healthy participants of both genders.
New Formulation	NCT03766984 ↗	Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac	Completed	Grünenthal GmbH	Phase 1	2015-06-07	The objective of the study was to evaluate whether or not there is a substantial pharmacokinetic interaction between diclofenac and tramadol in a new formulation of a fixed-dose combination of diclofenac 25 milligrams (mg) and tramadol 25 mg for oral administration. The study was conducted in healthy participants of both genders.

All Clinical Trials for diclofenac

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00090181 ↗	Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 4	2004-06-01	The purpose of this study is to evaluate the efficacy of MK0663 for the treatment of chronic low back pain and to investigate the overall safety and tolerability over four weeks of treatment.
NCT00092378 ↗	A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2003-09-01	This purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following bunionectomy surgery.
NCT00092703 ↗	Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2002-06-27	The purpose of this study is to compare the gastrointestinal tolerability of an investigational drug to an approved drug in the treatment of osteoarthritis during one year treatment period.
NCT00092742 ↗	Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2003-02-01	The purpose of this study is to evaluate the long-term safety of an investigational drug versus an approved drug for the relief of pain in patients with rheumatoid arthritis.
NCT00108992 ↗	Efficacy and Safety of Topical Diclofenac Combined With Oral Diclofenac in the Treatment of Knee Osteoarthritis	Completed	Nuvo Research Inc.	Phase 3	2004-02-01	Oral non-steroidal anti-inflammatory drugs (NSAIDs) are a recommended treatment for the symptoms of osteoarthritis of the knee. However, NSAIDs may cause a range of negative side effects, including stomach pain, heartburn, bleeding stomach ulcer, and liver or kidney abnormality. A topical NSAID may relieve pain and other symptoms of osteoarthritis of the knee, while minimizing the side effects common to oral NSAIDs. The purpose of this study is to determine the safety and effectiveness of a topical NSAID when used alone or when combined with an oral NSAID in the treatment of osteoarthritis of the knee.
NCT00121901 ↗	Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis?	Completed	Hvidovre University Hospital	Phase 3	2004-10-01	Post-ERCP pancreatitis can be a serious complication to ERCP. Two studies have shown a promising preventive effect of glyceryl nitrate. This study should provide a final answer to the clinical question: Does glyceryl nitrate prevent post-ERCP pancreatitis? The study is a prospective, randomized, double blind, placebo-controlled multicenter trial. The investigators intend to include 1600 patients from Norway, Sweden, Denmark, and France. The patients will receive either placebo or a glyceryl nitrate patch (15 mg/24 hours). Follow-up will occur after 7 days. The primary outcome measure will be post-ERCP pancreatitis, and secondary outcome measures will be mild, moderate and severe pancreatitis; post procedure pancreatitis-related mortality; and adverse events.
NCT00139646 ↗	Parecoxib in Renal Colic	Terminated	Pfizer	Phase 3	2002-04-01	This is a phase III, multicenter, randomized, single blind study designed to evaluate the efficacy and tolerability of a single dose of parecoxib compared with diclofenac in the treatment of acute pain due to renal colic.

Clinical Trial Conditions for diclofenac

Condition Name

Condition Name for diclofenac
Intervention	Trials
Pain	52
Osteoarthritis	24
Postoperative Pain	20
Pain, Postoperative	19

Condition MeSH

Condition MeSH for diclofenac
Intervention	Trials
Pain, Postoperative	69
Osteoarthritis	59
Osteoarthritis, Knee	38
Acute Pain	17

Clinical Trial Locations for diclofenac

Trials by Country

Trials by Country for diclofenac
Location	Trials
United States	468
United Kingdom	68
China	54
Egypt	44
India	43

Trials by US State

Trials by US State for diclofenac
Location	Trials
Texas	34
Florida	33
California	28
Pennsylvania	22
Ohio	19

Clinical Trial Progress for diclofenac

Clinical Trial Phase

Clinical Trial Phase for diclofenac
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	6
PHASE2	6

Clinical Trial Status

Clinical Trial Status for diclofenac
Clinical Trial Phase	Trials
Completed	292
Recruiting	66
Unknown status	45

Clinical Trial Sponsors for diclofenac

Sponsor Name

Sponsor Name for diclofenac
Sponsor	Trials
Cairo University	22
Novartis	18
Pfizer	14

Sponsor Type

Sponsor Type for diclofenac
Sponsor	Trials
Other	407
Industry	201
OTHER_GOV	9

Diclofenac: Clinical Trials Update, Market Analysis and 2030 Projection

Last updated: April 28, 2026

What is the current clinical-trials footprint for diclofenac?

Diclofenac is an established NSAID with extensive global use across oral, topical, ophthalmic, and injectables. The clinical-trials landscape in practice is dominated by (1) post-marketing studies, (2) comparative tolerability or formulation performance, and (3) indication-expansion trials in smaller populations. For business planning, the key practical takeaway is that diclofenac’s “active” pipeline value is now largely tied to formulation lifecycle strategy (lower GI risk positioning, improved local delivery, reduced dosing frequency) rather than first-in-class drug discovery.

Because diclofenac has long-standing approvals across multiple routes and indications, “clinical trial updates” for diclofenac generally do not behave like biotech pipelines where early efficacy signals drive valuation. Instead, trial activity clusters around:

• Product line differentiation (e.g., topical gel/patch vs oral vs ophthalmic formulations)
• Comparators against other NSAIDs
• Safety and real-world evidence consolidation
• Pharmacokinetic and bioequivalence studies tied to generics and reformulations

Actionable lens for stakeholders

• Development ROI: highest where formulation can defend differentiation (systemic exposure reduction, convenient dosing, patient adherence).
• Regulatory strategy: focus shifts to label durability and safety consistency, not novel efficacy outcomes.
• Competitive intensity: high in oral generics; competitive edges more likely in branded topical or specialty routes.

Where does diclofenac sit in the market today?

Diclofenac occupies one of the largest NSAID commercial categories globally. Market share varies by geography and route, but the category is characterized by:

• Mature demand: broad use in musculoskeletal pain, osteoarthritis, rheumatoid arthritis, and post-operative pain contexts.
• Channel dominance: OTC and prescription mixes differ by country.
• Price pressure: strong due to generic penetration for oral formulations in most major markets.
• Route bifurcation:
  • Oral diclofenac: mature and intensely genericized
  • Topical diclofenac: still supports higher brand pricing in several regions
  • Ophthalmic and specialty forms: smaller market sizes but can sustain brand differentiation

Market structure

• Brand vs generic split: brand strength is strongest in branded topical products and in markets where switching is constrained by prescriber habits, formulary placement, or patient preference.
• Competitive set: other NSAIDs (ibuprofen, naproxen, etodolac, celecoxib in markets where COX-2 has formulary access) plus localized competitors in topical segments.

What are the drivers of demand for diclofenac?

Primary demand drivers are structural and durable rather than dependent on a new mechanism:

1. Large addressable pain pool: chronic musculoskeletal pain and osteoarthritis manage over long horizons.
2. Clinical familiarity: entrenched prescriber and patient behaviors reduce adoption friction for existing products.
3. Formulation strategy: topical and specialty routes can capture incremental segments where systemic exposure is a concern.
4. Supply-chain depth: widespread manufacturing supports steady availability and low distribution risk.

What are the key commercial risks?

The risk profile for diclofenac is defined by policy and safety framing more than by clinical novelty:

• Cardiovascular and GI safety scrutiny: affects label perception, payer restrictions, and substitution behavior.
• Regulatory label tightening: can reduce eligible patient populations and influence formulary access.
• Generic price compression: limits margin capture for oral products.
• Switching risk: when payers incentivize alternative NSAIDs in formularies.

How do payer and regulatory dynamics affect pricing and access?

In mature NSAID markets, diclofenac’s commercial performance is often mediated through:

• Formulary tiering (preferred vs non-preferred NSAIDs)
• Quantity limits and step therapy
• Restriction by patient risk profile (cardiovascular or GI risk categories)

These dynamics tend to be more restrictive for oral formulations than for topical routes in many markets, which is why topical can maintain comparatively better pricing and defensibility.

What is the current pipeline value proposition for diclofenac?

For a molecule this mature, “pipeline” value is typically a function of:

• Lifecycle management: new strengths, new delivery systems, new dosing schedules
• Evidence packaging: post-marketing safety updates and tolerability claims
• Regulatory strategy: label extensions that support targeted reimbursement segments
• Manufacturing and cost position: generic manufacturing scale and compliance strength

Under this framework, diclofenac’s development is less about discovering new biology and more about optimizing commercial packaging.

Market analysis: sizing logic and route split

A full, exact market-size forecast requires up-to-date syndicated data and disaggregated route-level sales by geography. Here, the usable decision-grade approach is to model diclofenac’s category economics by route, since each route has different pricing elasticity and generic exposure.

Route-level economic model (framework used for projection)

Route	Demand drivers	Pricing pressure	Primary value lever
Oral	Chronic and acute musculoskeletal pain	High (genericized)	Distribution scale and contracts
Topical	Local pain management, adherence	Medium to moderate	Branded differentiation and clinical comfort
Ophthalmic (where used)	Eye inflammation/pain indications	Medium	Brand/label control and prescriber habits
Injectable (where used)	Perioperative and acute settings	Medium	Hospital formulary and procurement deals

Business implication: Most “growth” for diclofenac is likely to come from topline stability and mix shift toward topical/specialty products, not volume expansion in oral segments.

Diclofenac 2030 projection: expected industry trajectory

Given diclofenac’s maturity, a projection should not assume breakthroughs. The base-case expectation is:

• Low single-digit to mid single-digit revenue growth globally for the product class, driven by population aging, persistent pain prevalence, and mix shift to topical where applicable.
• Margin stability for topical and specialty where branded or semi-branded positions exist
• Continued margin compression for oral due to generic competition

Projection ranges (global) used for investment-grade planning

Metric	2025-2030 base-case	Key assumption
Category revenue growth	Low to mid single digits	Persistent demand + topical mix shift
Unit growth	Low (population-driven)	Pain prevalence growth offset by generic substitution
Pricing	Flat to declining	Generic gravity in oral; partial stabilization in topical
Operating profit	Diverges by portfolio	Topical/specialty defend margin better than oral

What would change the forecast? (Scenario triggers)

Even for a mature molecule, the forecast can shift on measurable triggers:

• Stronger restrictions on oral NSAID use in high-risk populations
• Payer policies that preferentially steer patients to COX-2 inhibitors or other NSAIDs
• Expanded topical reimbursement or formulary upgrades
• Competitive entry via new delivery systems or high-penetration generics in topical

For planning, monitor formulary changes and label updates by major regulators and payer formularies, because they transmit directly into market access.

Competitive landscape: how diclofenac’s positioning compares

Diclofenac competes inside NSAIDs against:

• Nonselective comparators: ibuprofen, naproxen, indomethacin, etodolac
• COX-2 selective (where formulary access and cost allow): celecoxib and related agents

Competitive advantage map

• Topical diclofenac: advantage in localized pain segments where systemic exposure is a payer and patient concern
• Oral diclofenac: advantage in cost-effective coverage and availability, but less defensible margin due to generics

Commercial implications for R&D and investment

If you are evaluating new diclofenac development

The most defensible projects are those that:

• Improve local exposure profiles or reduce systemic exposure
• Increase adherence through dosing convenience
• Create measurable differentiation that can survive generic substitution dynamics

If you are evaluating portfolio acquisition or partnership

The highest value is typically in:

• Topical and specialty segments with retained brand or semi-branded share
• Regions where formulary access is more stable
• Contracts tied to procurement where supply reliability is a binding criterion

Key Takeaways

• Diclofenac is a mature NSAID with clinical activity primarily centered on formulation lifecycle, post-marketing evidence, and comparative safety or performance rather than breakthrough efficacy.
• The market is dominated by persistent pain demand but constrained by generic price compression in oral products.
• Commercial growth through 2030 is most plausibly driven by mix shift toward topical and specialty routes plus incremental reimbursement stability, not by major molecular innovation.
• Forecasting should be route-led: oral remains pricing-pressured; topical and specialty carry the better margin defensibility.

FAQs

1. Is diclofenac’s clinical development likely to produce major new regulatory label expansion?
   Not typically; current development patterns for diclofenac are oriented around formulation and evidence updates.

2. Where is diclofenac most likely to maintain pricing power?
   Topical and specialty routes tend to sustain better relative pricing than oral due to differentiation and payer positioning.

3. What drives revenue more: volume or mix?
   Mix shift and route-level substitution patterns are more important than unit volume growth for a mature molecule.

4. What is the biggest risk to diclofenac market growth?
   Regulatory and payer restrictions that reduce eligible patient populations for oral NSAIDs.

5. How should an investor model diclofenac revenue through 2030?
   Use route-level assumptions (oral price compression vs topical stability) rather than assuming uniform growth across formulations.

References

No sources were provided in the prompt, and no external citations are included.